Novavax Inc

NVAX · Biotechnology · $1.7B
Powering up
NVAX
$10.11
▲ +1.10%
09/18 O 9.89 H 10.14 L 9.76 C 10.11 ▲ +1.10%
Vol 11.1M RS 56
RS rating56
Now vs pivot (%)−0.88%
Tightening (ATR ratio)1.17×
Volume dry-up1.28×
Up/down volume, net0.25
From 52-week high16%
failed pokeplayed out
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 4.2 weeks and fell 23% from its ceiling at its deepest. The pivot is $10.20, and the stock closed 0.9% below it. Its relative strength rating is 56.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
  1. Earningstentativein 48d
    Quarterly earnings
    Nov 5, 2026
Flagged by the market sweep
GappedTape · 2026-09-18
+7.0%
GappedTape · 2026-09-11
-5.6%

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Novavax Inc (NVAX) — The Tape